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Abstract: Inflammatory bowel disease (IBD) is a chronic and life-long disease characterized by
gastrointestinal tract inflammation. It is caused by the interplay of the host’s genetic predisposition
and immune responses, and various environmental factors. Despite many treatment options, there
is no cure for IBD. The increasing incidence and prevalence of IBD and lack of effective long-term
treatment options have resulted in a substantial economic burden to the healthcare system worldwide.
Biologics targeting inflammatory cytokines initiated a shift from symptomatic control towards
objective treatment goals such as mucosal healing. There are seven monoclonal antibody therapies
excluding their biosimilars approved by the US Food and Drug Administration for induction and
maintenance of clinical remission in IBD. Adverse side effects associated with almost all currently
available drugs, especially biologics, is the main challenge in IBD management. Natural products
have significant potential as therapeutic agents with an increasing role in health care. Given that
natural products display great structural diversity and are relatively easy to modify chemically, they
represent ideal scaffolds upon which to generate novel therapeutics. This review focuses on the
pathology, currently available treatment options for IBD and associated challenges, and the roles
played by natural products in health care. It discusses these natural products within the current
biodiscovery research agenda, including the applications of drug discovery techniques and the search
for next-generation drugs to treat a plethora of inflammatory diseases, with a major focus on IBD.
Keywords: inflammatory bowel diseases; ulcerative colitis; Crohn’s disease; small molecule drugs;
biologics; anti-inflammatory; natural products drugs
1. Introduction
Inflammatory bowel disease (IBD) includes ulcerative colitis (UC) and Crohn’s disease (CD).
UC was first described in 1859 [1], and CD in 1932 [2]. Both UC and CD are chronic and debilitating
diseases without a real cure. As of 2017, 6.8 million IBD cases were reported globally, with an
increase in age-standardized prevalence rates from 79.5 per 100,000 population in 1990 to 84.3 per
100,000 population in 2017 [3]. More than 1.6 million people in the United States [4], 250,000 in the
United Kingdom [5], 260,000 in China [6], and 85,000 in Australia are affected by IBD [7]. Over the past
few decades, IBD was most dominant in the western world as both the rate of incidence and prevalence
were higher compared to developing countries. Recently, however, IBD incidence has increased rapidly
in many Asian countries [5] with consistently rising trends, particularly in Japan, Korea, Hong Kong,
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and mainland China [8]. In Asia, males between the ages of 20 to 39 years are affected more by CD, and
there is also a higher prevalence of ileocolonic CD, which is not the case in western countries [9–11].
There is a lack of national registries in many developing Asian, African, and Latin American countries
and, therefore, much less is known about the incidence and prevalence of IBD.
IBD causes substantial morbidity [12] and heavy productivity losses [13,14]. The increasing trends
in the rate of incidence and prevalence of IBD and lack of a cure or effective long-term treatment
options have resulted in a substantial financial burden to the healthcare system worldwide [3,15,16].
When Park et al. [17] analyzed healthcare costs for 52,782 IBD patients in the United States on a per-year
basis, IBD patients incurred a greater than 3-fold higher direct cost of care compared to non-IBD patients
(US $22,987 vs. US $6956 per-member per-year paid claims) and more than twice the out-of-pocket
costs (US $2213 vs. US $979 per-year reported costs), with all-cause IBD costs rising since 2013.
Moreover, IBD patients have to bear significantly higher cost associated with the time they spend on
their healthcare, unlike non-IBD patients. Similarly, Australia spends approximately AU $100 million
per annum for IBD related hospitalization costs, more than AU $380 million related to productivity
loss, and an additional $2.7 billion for other financial and economic costs [18]. The financial burden
for IBD is highest during the first year of diagnosis, followed by a more stabilized cost pattern by
seven to eight years after diagnosis. However, treatment costs tend to rise again after this period [17].
The fluctuation in the financial burden can be attributed to either age-related or healthcare-related
factors, including inconsistent access to health care, support and education, and insecure funding
for IBD-treating hospitals. Treatments (biologics, opioids, or steroids), emergency department use,
and health care services associated with relapsing disease, anemia, or mental health comorbidity are
some of the critical factors that may cause financial burden to all countries until a cure for IBD is
established [17].
Despite the huge financial cost to the health care system and the morbidity burden faced by
many countries, effective treatments for IBD remain elusive for many reasons. Recent reviews by
Jeong et al. [19], Neurath [20], Kaplan [15], Ananthakrishnan [21], and Ruel et al. [22] highlight the
epidemiology and risk factors for IBD, associated global health burden, and current therapeutic targets.
There is, however, limited review coverage of the role of natural products in treating IBD. This current
scoping review explores the causative factors, challenges in current treatment options, and the status
of drug discovery from natural products for combating IBD.
2. Diagnosis and Pathophysiology of Inflammatory Bowel Disease
Both CD and UC show heterogeneity in many clinical and pathological features. They are
distinguishable by their location and nature of inflammation (Figure 1). Unlike UC, which attacks
colonic mucosa, CD can affect any part of the gastrointestinal (GI) tract [23]. Both conditions share
clinical features like extra-intestinal manifestation, but hematochezia and passage of mucus or pus are
common only in UC. Fistulas, perianal disease, colonic and small bowel obstruction is common in
CD. Cryptitis and crypt abscesses are observed in both UC and CD, while crypt architecture is more
distorted in the case of UC [24]. Both UC and CD show relapsing intestinal inflammation. Intermediate
colitis (IC) sometimes does not present distinct clinical features of either UC or CD, particularly in
colectomy specimens, rendering it hard to distinguish UC from CD. Although IC is not a unique disease
or distinct clinical entity, it accounts for around 10% of the total IBD cases involving the colon [25],
and this figure has not changed over the last 30 years [26]. Currently, IC is usually diagnosed when a
distinction between UC and CD becomes difficult. A standard positive diagnostic test for IC is not
yet available.
J. Clin. Med. 2020, 9, 1273 3 of 39
J. Clin. Med. 2020, 9, x FOR PEER REVIEW 3 of 39 
 
 
Figure 1. Different types of Inflammatory Bowel diseases. (A) Ulcerative colitis: proctitis, left-sided 
colitis, and extended colitis; (B) Crohn’s disease: Ileocecal Crohn’s disease, Crohn’s colitis, and 
Fistulising Crohn’s disease. Red indicates area of inflammation. 
2.1. Ulcerative Colitis 
UC causes inflammation and ulceration of the inner lining of the colon and rectum (the large 
bowel). There is no gender predominance in UC, and the peak age of disease onset is between ages 
30–40 years [27]. Symptoms usually include diarrhea, abdominal pain, fatigue, loss of appetite and 
weight, and anemia. The severity of symptoms depends upon how much of the colon is affected or 
inflamed. Inflammation in UC is non-specific and may occur in the rectum (proctitis), left semicolon 
(left-sided colitis) or entire colon (extensive colitis or pancolitis) (Figure 2) [28]. 
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2.1. Ulcerative Colitis
UC causes inflammation and ulceration of the inner lining of the colon and rectum (the large
bowel). There is no gender predominance in UC, and the peak age of disease onset is between ages
30–40 years [27]. Symptoms usually include diarrhea, abdominal pain, fatigue, loss of appetite and
weight, and anemia. The severity of symptoms depends upon how much of the colon is affected or
inflamed. Inflammation in UC is non-specific and may occur in the rectum (proctitis), left semicolon
(left-sided colitis) or entire colon (extensive colitis or pancolitis) (Figure 2) [28].
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Figure 2. Types of ulcerative colitis and diagnosis. 
Currently, there is no ‘gold standard’ test to diagnose UC [29]. Diagnosis of UC relies on test 
results obtained by colonoscopy, histopathology, blood testing, fecal examination, and radiological 
studies [30]. Patients diagnosed with UC at an older age are at lower risks of colectomy than those 
diagnosed at a younger age (below 16 years) [30]. According to a meta-analysis of population-based 
cohort studies, the risk of developing colorectal cancer is 2.4-fold higher in patients with UC, and the 
risk is higher in males than females and for those diagnosed with UC and extensive colitis at a young 
age [31]. 
The pathogenesis of UC and CD is considerably distinct from each other. The change in luminal 
microbial diversity (dysbiosis), impairment of epithelial, and mucus layer barrier via disruption of 
tight junctions are strongly implicated in the pathogenesis of UC. Figure 3 shows an overview of the 
pathophysiology of UC. Although UC patients exhibit lower diversity of Firmicutes and a higher 
proportion of Gamma-proteobacteria and Enterobacteriaceae [32], and sulfite reducing 
deltaproteobacteria [33], whether such changes are intestinal inflammation-driven or vice versa 
remains controversial. Interleukin (IL)-13 produced by T helper type 2 (Th2) cells and non-classical 
natural killer T cells (NKT cells) also mediates UC [34–36] as it synergizes with tumor necrosis factor 
alpha (TNF-α) to regulate the expression of genes responsible for the formation of tight junction entero-
epithelial cells [37]. IL-13 also disturbs the membrane integrity by increasing the rate of cell apoptosis 
(which intensifies upon exposure to TNF-α), and by changing the protein composition of the tight 
junctions [38]. An impairment of tight junctions increases gut permeability, leading to an enhanced 
influx of luminal antigens. Antigen-presenting cells (APC) such as macrophages and dendritic cells 
become activated upon recognizing non-pathogenic bacteria (commensal microbiota) through Toll-
like receptors (e.g., Toll-like receptor 2 (TLR2) and TLR4) [39]. Activated APCs in turn initiate 
differentiation of naïve CD4+ (cluster of differentiation 4) T-cells into different subsets of effector T 
helper cells such as Th2, Th9, and regulatory T cells (Treg) in UC. In the inflamed lamina propria of 
UC patients, the expression of IL-4, which is a signature cytokine of Th2 cells, is dominated by high-
level expression of other Th2-associated cytokines such as IL-5 and IL-13, and the Th2 master 
transcription factor GATA binding protein 3 (GATA3) [40]. Thus, UC is predominantly a Th2-
mediated immune disorder, but considering the low-level expression of IL-4, the role of Th2 cells as 
a whole in UC remains inconclusive. IL-9-producing Th9 cells are also associated with UC as they 
prevent mucosal wound healing and disrupt protective functions of the mucus layer [41]. 
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al ha (TNF-α) to regulate the expression of genes responsible for the formation of tight junction
entero-epithelial cells [37]. IL-13 also disturbs the membrane integrity by increasing the rate of cell
apoptosis (which intensifies upon exposure to TNF-α), and by changing the rotein composition
of the tight junctions [38]. An impairment of tight junctions increases gut permeability, leading to
an enhanced influx of luminal antigens. Antigen-presenting cells (APC) such as macrophages and
dendritic cells become activated upon recognizing non-pathogenic bacteria (commensal microbiota)
through Toll-like receptors (e.g., Toll-like receptor 2 (TLR2) and TLR4) [39]. Activated APCs in turn
initiate differentiation of naïve CD4+ (cluster of differentiation 4) T-cells into different subsets of effector
T helper cells such as Th2, Th9, and regulatory T cells (Treg) in UC. In the inflamed lamina propria
of UC patients, the expression of IL-4, which is a signature cytokine of Th2 cells, is dominated by
high-level expression of other Th2-associated cytokines such as IL-5 and IL-13, and the Th2 aster
transcription factor GATA binding protein 3 (GATA3) [40]. Thus, UC is predominantly a Th2-mediated
immune disorder, but considering the low-level expression of IL-4, the role of Th2 cells as a whole
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Figure 3. Pathophysiology of Ulcerative Colitis. Impairment of tight junctions and the mucous layer 
leads to increased permeability of the intestinal epithelium, resulting in more uptake of luminal 
antigens. Antigen presenting cells (APC) become activated upon recognizing non-pathogenic bacteria 
(commensal microbiota) through Toll-like receptors (TLRs). Activated APC initiate differentiation of 
naïve CD4+ T-cells into Th-2 effector cells (which produce pro-inflammatory cytokines such as TNF-α, 
IL-5, IL-6, and IL-13). TNF-α and IL-1 activate nuclear factor κB (NF-κB) pathway, which facilitate 
expression of pro-inflammatory and cell survival genes. Binding of integrin-α4β7 bearing T cells to the 
mucosal adhesion molecule MAdCAM-1 facilitate entry of more T cells into the lamina propria. 
Recruitment of circulating leucocytes due to the upregulation of inflammatory chemokines 
(chemokine ligands: CXCL1, CXCL3, CXCL8 and CXCL10) perpetuates the inflammatory cycle. 
MAdCAM-1, mucosal addressin cell adhesion molecule-1; IL, interleukin; TNF-α, tumor necrosis 
factor-alpha; TGF-β, transforming growth factor-beta; NKT, natural killer T; DC, dendritic cell; Th, T 
helper; GATA3, GATA binding protein 3; IRF4, interferon regulatory factor 4; PU.1, purine-rich PU-
box binding protein; FOXP3, Forkhead box protein 3. 
High levels of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) causes increased 
recruitment of gut-associated lymphocytes to healthy gastrointestinal tract and sites of inflammation, 
implicating its role in the pathogenesis of IBD. Increased expression of MAdCAM-1 in the endothelium 
of the inflamed colon of rats induced by peptidoglycan-polysaccharide, and subsequent attenuation of 
colitis by anti-MAdCAM-1 antibody, imply a vital role of this molecule in the development of colitis [42]. 
MAdCAM-1 is equally abundant in the inflamed mucosa of both UC and CD, but MAdCAM-1+ venules 
are more abundant in the deeper layers of intestinal tissue from CD patients compared to UC (p < 0.001), 
and might account for the unique transmural inflammation in CD [43]. 
The mortality among the UC patients results mainly from comorbid conditions such as 
infectious and cardiovascular disease, and colon and biliary tract cancers [44]. Postoperative 
complications and comorbidity are additional factors for increased mortality within the first 2 years 
after diagnosis among patients >50 years of age and those diagnosed with extensive colitis [45]. 
2.2. Crohn’s Disease 
CD is a chronic inflammatory disorder of the gastrointestinal tract affecting most commonly the 
terminal ileum, caecum, perianal area, and colon. Symptoms of CD are often insidious, making 
diagnosis difficult. However, symptoms such as chronic or nocturnal diarrhea, abdominal pain, 
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FOXP3, Forkhead box protein 3.
High levels of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) causes increased
recruitment of gut-associated lymphocytes to healthy gastrointestinal tract and sites of inflammation,
implicating its role in the pathogenesis of IBD. Increased expression of MAdCAM-1 in the endothelium
of the inflamed colon of rats induced by peptidoglycan-polysaccharide, and subsequent attenuation of
colitis by anti-MAdCAM-1 antibody, imply a vital role of this molecule in the development of colitis [42].
MAdCAM-1 is equally abundant in the inflamed mucosa of both UC and CD, but MAdCAM-1+
venules are more abundant in the deeper layers of intestinal tissue from CD patients compared to UC
(p < 0.001), and might account for the unique transmural inflammation in CD [43].
The mortality among the UC patients results mainly from comorbid conditions such as infectious
and cardiovascular disease, and colon and biliary tract cancers [44]. Postoperative complications and
comorbidity are additional factors for increased mortality within the first 2 years after diagnosis among
patients >50 years of age and those diagnosed with extensive colitis [45].
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2.2. Crohn’s Disease
CD is a chronic inflammatory disorder of the gastrointestinal tract affecting most commonly
the terminal ileum, caecum, perianal area, and colon. Symptoms of CD are often insidious, making
diagnosis difficult. However, symptoms such as chronic or nocturnal diarrhea, abdominal pain, bowel
obstruction, weight loss, fever, or night sweats are critical parameters for initial diagnosis [46] besides
other endoscopic or pathological features (Figure 4).
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Delayed diagnosis of CD causes increasing bowel damage, fibrosis, and disability. Besides 
clinical assessment, blood- and fecal-based biomarkers are also used as an additional tool by 
clinicians to distinguish IBD from non-inflammatory diarrhea and for their management. For 
example, biomarkers such as fecal calprotectin (FC) is useful for screening IBD patients for 
endoscopic evaluation, and fecal lactoferrin in assessing the course of disease activity and healing 
[47–49]. And FC measurement is considered a promising non-invasive tool for clinical management 
of IBD. Although the choice of the optimal cut-off value for FC measurement remains a concern, 
higher FC cut-off value is known to maximize the accuracy of the diagnosis of IBD, particularly in 
UC compared to CD [50]. We did not elaborate on the role of FC in the clinical management of IBD, 
as it is reviewed in-depth by Mumolo et al. [51]. 
CD is a Th1 cell-mediated disorder. Small bowel inflammation in CD exhibits an increased level 
of proinflammatory cytokines such as interferon-gamma (IFN-γ) and IL-17A (produced by Th1 and 
Th17 cells, respectively) [35]. Moreover, the Th17 pathway (mediated by Th17 cell-derived IL-17) in 
turn influences the Th-1 response [52]. IL-6, IL-23, and transforming growth factor-beta (TGF-β), 
which are produced by innate immune cells and APCs, influences the IL-17 pathway (Figure 5). The 
high-level expression of transcription factors (e.g., STAT4 and T-bet) and cytokine receptors (e.g., IL-
12Rβ2) promotes Th1 cell differentiation, which is characteristic of inflamed lamina propria of CD 
patients [53]. IL-12 derived activated APCs stimulates the Th1 master transcription factor T-bet [54]. 
The expression of IL-23 by ileal dendritic cells stimulates IL-17 production, and as a result, both IL-
17 and IL-23 are present in elevated levels in CD patients [54]. Thus, the development of CD is 
associated with both Th-1 and Th17 pathways. The mortality rate in CD is mainly due to pulmonary 
disease and cancers of the biliary tract, lymphoid and hematopoietic tissues [44]. 
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elayed diagnosis of CD causes increasing bowel damage, fibrosis, and disability. Besides clinical
assessment, blood- and fecal-based biomarkers are also used as an additional tool by clinicians to
distinguish IBD from non-inflammatory diarrhea and for their management. For example, biomarkers
such as fecal calprotectin (FC) is useful for screening IBD patients for endoscopic evaluation, and fecal
lactoferrin in assessing the course of disease activity and healing [47–49]. And FC measurement is
considered a pro ising non-invasive tool for clinical management of IBD. Although the choice of
the optimal cut-off value for FC measure ent remains a concern, higher FC cut-off value is known
to maximize the accuracy of the diagnosis of IBD, particularly in UC compared to CD [50]. We did
not elaborate on the role of FC in the clinical management of IBD, as it is reviewed in-depth by
Mumolo et al. [51].
CD is a Th1 cell-mediated disorder. Small bowel inflam ation in CD exhibits an increased level of
proinflammatory cytokines such as interferon-gamma (IFN-γ) and IL-17A (produced by Th1 and Th17
cells, respectively) [35]. Moreover, the Th17 pathway (mediated by Th17 cell-derived IL-17) in turn
influences the Th-1 response [52]. IL-6, IL-23, and transforming growth factor-beta (TGF-β), which are
produced by innate immune cells and APCs, influences the IL-17 pathway (Figure 5). The high-level
expression of transcription factors (e.g., STAT4 and T-bet) and cytokine receptors (e.g., IL-12Rβ2)
promotes Th1 cell differentiation, which is characteristic of inflamed lamina propria of CD patients [53].
IL-12 derived activated APCs stimulates the Th1 master transcription factor T-bet [54]. The expression
of IL-23 by ileal dendritic cells stimulates IL-17 production, and as a result, both IL-17 and IL-23 are
present in elevated levels in CD patients [54]. Thus, the development of CD is associated with both
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Th-1 and Th17 pathways. The mortality rate in CD is mainly due to pulmonary disease and cancers of
the biliary tract, lymphoid and hematopoietic tissues [44].J. Clin. Med. 2020, 9, x FOR PEER REVIEW 7 of 39 
 
 
Figure 5. Pathophysiology in Crohn’s disease. The uptake of luminal microflora stimulates APCs (e.g., 
dendritic cells and macrophages) which in turn produce proinflammatory cytokines such as TNF-α, 
IL-6, and IL-23. Activated APCs facilitate subsequent differentiation of naïve CD4+ Th cells into Th1 
and Th17 via expression of master transcription factors. Inside the high endothelial venule, binding 
of α4β7-bearing lymphocytes to MAdCAM-1 causes entry of more T cells into the lamina propria. 
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3. Causes and Risk Factors of Inflammatory Bowel Disease 
The Hygiene Hypothesis is a central theme to the growing incidence of IBD, but it is still difficult 
to pinpoint which particular factors are responsible for causing IBD. Strachan first proposed the 
Hygiene Hypothesis in 1989 to explain the increasing incidence of atopy (allergic disorders) [55]. 
Later, many authors claimed through epidemiological studies and various experimental models that 
autoimmune disorders could be a result of broad environmental, infectious burden rather than 
individual behavior/hygiene [56–59]. According to the Rook’s reinterpretation of hygiene hypothesis 
(Old Friends Hypothesis as proposed in 2003), immunoregulatory disorders would occur first in 
those individuals with reduced/minimal contact with pathogens including commensal microbes and 
helminths (old friends) that are known to prime immunoregulation (Treg activity) in the human gut [60]. 
The rapid rise in the incidence of IBD over the last century in both developing and developed 
countries [3,15] could be related to improved hygiene practices such as access to clean water, non-
contaminated food, and reduced family size [61]. While the definitive cause of IBD remains elusive 
and unknown, many studies point to 10 different causative factors (Figure 6) [23], with three major 
factors being genetic, environmental, and diet (which influences the host’s gut microbiota). 
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3. Causes and Risk Factors of Inflammatory Bowel Disease
The Hygiene Hypothesis is a central theme to the growing incidence of IBD, but it is still difficult
to pinpoint which particular factors are responsible for causing IBD. Strachan first proposed the
Hygiene Hypothesis in 1989 to explain the increasing incidence of atopy (allergic disorders) [55].
Later, many authors claimed through epidemiological studies and various experimental models
that autoimmune disorders could be a result of broad environmental, infectious burden rather than
individual behavior/hygiene [56–59]. According to the Rook’s reinterpretation of hygiene hypothesis
(Old Friends Hypothesis as proposed in 2003), immunoregulatory disorders would occur first in
those individuals with reduced/minimal contact with pathogens including commensal microbes and
helminths (old friends) that are known to prime immunoregulation (Treg activity) in the human
gut [60]. The rapid rise in the incidence of IBD over the last century in both developing and
developed countries [3,15] could be related to improved hygiene practices such as access to clean
water, non-contaminated food, and reduced family size [61]. While the definitive cause of IBD remains
elusive and unknown, many studies point to 10 different causative factors (Figure 6) [23], with three
major factors being genetic, environmental, and diet (which influences the host’s gut microbiota).
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3.1. Genetics 
Genome-wide association studies identified 163 susceptible gene loci in IBD (with 110 common, 
30 CD specific, and 23 UC specific) [62], highlighting the role of genetics in IBD pathogenesis. 
However, more than 50% of IBD susceptible gene loci are also associated with other inflammatory 
and autoimmune diseases [63]. MDR1 (multidrug resistance 1) gene in human chromosome 7 is one 
such gene that is associated with the pathogenesis of UC [54]. A comprehensive understanding of the 
mechanisms of IBD pathogenesis induced by genetic factors requires studying the role of an 
individual gene, which can be a challenging task. However, less than 50% concordance for IBD in 
twins represents the significant role that environmental factors might have in the development of 
IBD [64]. Another study conducted by Thompson et al. in British twins also reported similar (only 
17% concordance for IBD) results among identical twins [65]. Moreover, the concordance between 
two disease conditions (CD and UC) among twins is not the same. Analysis of a Swedish twin cohort 
showed higher concordance (50%) for CD than for UC (18.8%), suggesting that genetic influence or 
heritability is higher in CD than in UC [64,66,67]. 
3.2. Environmental Factors 
After extensive studies trying to determine the role of genetics in the pathogenesis of IBD have 
not yielded adequate evidence, many assume environmental factors to have a more significant role 
than genetics. Numerous studies have analyzed the linkage between various environmental factors 
and the development of IBD. When Khalili et al. studied the association of geographical variation 
with the incidence of IBD (both CD and UC) in two large prospective cohorts of US women (175,912), 
they found a higher incidence of both CD and UC among women residing in the northern latitudes, 
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People living in higher altitudes are also more likely to have vitamin D deficiency due to insufficient 
exposure to sunlight [70]. Lack of vitamin D is also considered a possible cause of IBD since vitamin 
D receptor knock-out mice develop severe inflammation [71]. 
Numerous studies are suggesting a role for the environment in the pathogenesis of IBD, notably 
from a migration perspective [72–74]. For instance, children of immigrants who arrived in Canada at 
a younger age have an increased risk of IBD [75]. While Zoetendal et al. compared the risk of 
developing IBD among African-Americans and Africans inhabiting semi-urban (westernized) and 
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more than 50% of IBD susceptible gene loci are also associated with other inflammatory and autoi mune
diseases [63]. MDR1 (multidrug resistance 1) gene in human chromosome 7 is one such gene that is
associated with the pathogenesis of UC [54]. A comprehensive understanding of the mechanisms of
IBD pathogenesis induced by genetic factors requires studying the role of an individual gene, which can
be a challenging task. However, less than 50% concordance for IBD in twins represents the significant
role that environmental factors might have in the development of IBD [64]. Another study conducted
by Thompson et al. in British twins also reported similar (only 17% concordance for IBD) results
among identical twins [65]. Moreover, the concordance between two disease conditions (CD and UC)
among twins is not the same. Analysis of a S edish twin cohort showed higher concordance (50%)
for CD than for UC (18.8%), suggesting that genetic influence or heritability is higher in CD than in
UC [64,66,67].
3.2. Environmental Factors
After extensive studies trying to determine the role of genetics in the pathogenesis of IBD have
not yielded adequate evidence, many assume environmental factors to have a more significant role
than genetics. Numerous studies have analyzed the linkage between various environmental factors
and the development of IBD. When Khalili et al. studied the association of geographical variation with
the incidence of IBD (both CD and UC) in two large prospective cohorts of US women (175,912), they
found a higher incidence of both CD and UC among women residing in the northern latitudes, which
could be attributable to less exposure to sunlight or ultraviolet B (UV-B) radiation [68]. UV-B radiation
induces UV-Treg cells that have the potential to suppress inflammatory responses [69]. People living
in higher altitudes are also more likely to have vitamin D deficiency due to insufficient exposure to
sunlight [70]. Lack of vitamin D is also considered a possible cause of IBD since vitamin D receptor
knock-out mice develop severe inflammation [71].
Numerous studies are suggesting a role for the environment in the pathogenesis of IBD, notably
from a migration perspective [72–74]. For instance, children of immigrants who arrived in Canada
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at a younger age have an increased risk of IBD [75]. While Zoetendal et al. compared the risk of
developing IBD among African-Americans and Africans inhabiting semi-urban (westernized) and
rural environments respectively, the risk was significantly lower among those who were born and
raised (first five years) in unhygienic environments like livestock farms compared to those living in
the city [76]. Selective exposure to various environmental factors or conditions is also responsible for
determining the microbiome composition. A study carried out in South Africa observed distinct gut
microbiome composition in genetically similar populations in rural areas versus urban areas [77], where
rural subjects contained significantly lesser Bacteriodetes populations than semi-urban and urban
subjects. While a similar comparative study from India showed a dominance of phyla Bacteriodetes
and Proteobacteria in the gut microbiome of rural subjects, phyla Firmicutes, and Lactobacillus in urban
subject [78]. These findings indicate that exposure to different environmental conditions/lifestyles can
influence the microbiome composition among a similar population.
3.3. Microbiota
The commensal human gut microbiota is essential for maintaining intestinal epithelial homeostasis
and protection from mucosal injury [79]. The human lower GI tract has 1014 microbial cells [80], and
Bacteriodetes and Firmicutes are the two most dominant phyla in the gut [81]. The gut microbiome
determines the normal functioning of human health. For example, fibrinolytic bacteria degrade
polysaccharides in the gut into smaller carbohydrates and short-chain fatty acids [82], and microbiota
of the lower GI tract use dietary fiber as a source of energy [83]. Any changes in the composition of the
healthy microbiota (dysbiosis) in the gut can trigger abnormal inflammatory responses. Firmicutes
species, such as Faecalibacterium prausnitzii, has been reported to be poorly represented in patients with
active IBD compared to healthy subjects [84]. The study conducted by Martin et al. further supports the
protective role of this species, where intragastric administration of F. prausnitzii significantly decreased
the severity of colitis in the trinitrobenzene sulfonic acid (TNBS)-induced mouse model of colitis [85].
The host must maintain a balance between recognizing pathogenic from commensal microbial species,
as any disturbance in the composition of commensal species could trigger abnormal inflammatory
responses such as IBD.
3.4. Diet and Smoking
Diet influences the composition of the microbiota and their metabolic activity in the human gut [86].
There is a growing concern that the western diet, rich in fats and sugars, is responsible for the change
in the diversity and metabolic activity of human gut microbiota, thereby contributing to the increasing
incidence of IBD [87,88]. The increase in the abundance of Bilophila wadsworthia due to an animal-based
diet can facilitate the growth of microorganisms that can trigger IBD [87,88]. Moreover, B. wadsworthia
also produces hydrogen sulfide that can cause damage to intestinal tissues [86]. Long-term dietary
pattern influences the development of IBD [89]. For instance, the intake of fruits decreases the risks
of developing CD [90], although the underlying mechanism is yet to be understood. Smoking is
one of the contradictory factors linked to IBD. While smoking is harmful to CD patients, reports
show beneficial in UC [63]. The positive effect of smoking in UC is evident from the “Boston Drugs
Surveillance Program” [91], ”UC patients in Birmingham, England” [92], and ”Oxford Family Planning
Association Contraceptive Study” [93]. Additionally, the transdermal treatment of active UC patients
with nicotine patches also showed better remission compared to the placebo group [94]. However, it is
still controversial, and more research is required to determine if nicotine is one of the active components
of cigarette smoking that is responsible for the beneficial effects on the UC disease course.
3.5. Sleep Deprivation, Stress, and Physical Inactivity
Inadequacy of sleep and psychological distress are additional intrinsic factors known to associated
with inflammation and the inflammation system. Sleep disturbances are said to be common in IBD
patients [95,96]. Some studies [97,98] have reported that symptoms of depression and anxiety cause
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clinical recurrence in IBD patients. However, stressful life events are not associated with the onset of
inflammatory disease [99]. Alteration of sleep pattern or circadian rhythms [100] and insufficient sleep
(<6 h/day) [96] has a direct impact on disease course and severity. A study involving 136 Japanese IBD
patients found sleep disturbances as a potential risk factor of disease flare-up for both UC and CD
within one year [95], but a similar kind of study (3173 IBD patients with sleep disturbances) conducted
by Ananthakrishnan et al. [101] could observe an increased risk of disease flares only in CD within
6 months. A positive correlation between psychological distress and IBD flare-ups [102,103] indicates
the need for timely psychological therapy in IBD patients.
3.6. Appendectomy
Appendectomy (i.e., surgical removal of the appendix) and its association with the development
of UC and CD is a scarcely explored area of research [104]. Few studies involving both humans as well
as animal models showed evidence for a role of the appendix in gastroenterology. T-cell receptor-α
mutant mice (TCR-α−/−) appendectomized at a young age (3–5 weeks old) contained more mesenteric
lymph node (MLN) cells compared to the placebo group (sham-operated TCR- α−/− mice), indicating
that the appendix could be an important site for priming MLN cells involved in causing IBD [105].
Similarly, Mombaerts et al. also found that an increase in the number of MLN cells in TCR-α−/−
mice is related to the development of IBD [106]. A few studies and case reports have also shown
the positive effect of appendectomy on the clinical course of UC in human subjects. A study of IBD
patients in Australia confirmed that appendectomy before diagnosis delays disease onset of both UC
and CD and results in fewer flare-ups in the case of UC when compared with patients without prior
appendectomy [107]. A case report from Korea also confirmed that a patient with UC experienced a
more extended period of remission after appendectomy [108]. However, the therapeutic relationship
between CD and appendectomy remains inconclusive. [30].
3.7. Antibiotic Use
A leading hypothesis in the etiology of IBD is the alteration in the human gut microbiota
that triggers abnormal inflammatory responses, including IBD. Multiple factors are assumed to be
responsible for inducing gut dysbiosis. Childhood exposure to antibiotics is one among them [109].
Children exposed to antibiotics at an early stage [109–112] and adults who had medication for acute
gastroenteritis [113] possess higher risks for IBD. The frequency of use of antibiotics and the age at
the time of use may have a varying effect as risks for IBD tend to decrease with increasing age at the
time of exposure [114]. Regular intake of non-steroidal anti-inflammatory drugs like aspirin showed a
strong positive correlation with only CD [115].
4. Current Treatment Options for IBD
4.1. Conventional Treatments
Prompt diagnosis and identifying the specific treatment goals (e.g., mucosal healing) can help to
create better long-term outcomes for patients. As there is no “gold standard” to define disease severity;
thus, only working definitions of disease activity are available to help guide IBD therapy. Figure 7
below, adapted from Ordás et al. [116] and Knutson et al. [117], presents an overview of currently
available treatment algorithms for UC and CD. The main conventional treatments for IBD are biologics,
oral corticosteroids, and salicylates, discussed in the subsequent sections.
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4.1.1. Small Molecule Drugs
Small molecules represent a potential source of selective drugs in IBD. Many small molecule drugs
(SMDs) such as corticosteroids (e.g., budesonide, prednisone), immunomodulators (e.g., azathioprine,
6-mercaptopurine, and methotrexate), and aminosalicylates (e.g., sulfasalazine and mesalazine) came
into clinical practice as early as 1955 for IBD [118,119]. SMDs (mol. Wt. <1000 Da) have stable
structures, and their cost of production is also comparatively cheaper than biologics. The shorter
half-life of SMDs is another advantage, particularly during situations like infection, surgery, and
pregnancy when rapid elimination of the drug is required [120]. Moreover, unlike biologics requiring
the parenteral route for administration, oral SMDs can boost a patient’s satisfaction and enhance
treatment adherence and efficacy [121].
The SMD tofacitinib [122] has recently proven to be safe and effective in the induction and
maintenance of clinical remission in UC. During phase 3, randomized, double-blind, placebo-controlled
trials of tofacitinib therapy in 905 adults with moderate to severe UC, approximately 18% achieved
clinical remission in 8 weeks as compared to 6% in the placebo group patients [123]. Tofacitinib under
two different trade names (XEL JANZ® (Pfizer Inc., Groton, NY, USA) and XEL JANZ XR® (Pfizer Inc.,
Groton, NY, USA) appeared in the market since 2018 as the first drug of the Janus-kinase (JAK) inhibitor
class, and it has displayed efficacy against moderate to severe UC with an excellent safety profile [124].
Aminosalicylate (5-ASA) and its derivatives, such as mesalamine [122] is another excellent example
of SMD in the therapeutic management of IBD. However, some SMDs, including corticosteroids, are
associated with adverse side effects. Sulfasalazine is associated with allergic and dose-dependent
intolerant side effects [125]. Besides the SMDs mentioned above, there are 22 additional SMDs under
clinical development for the treatment of IBD, including JAK-inhibitors, sphingosine-1-phosphate
receptor modulators [121].
4.1.2. Biologics
Biologics, or biological agents or biological response modifiers, are a group of molecules, including
recombinant cytokines, monoclonal antibodies, and specific antagonists of cytokines and soluble
receptors that are involved in modulating inflammation during immune-mediated processes. Biologics
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are more immunogenic than SMDs [126]. They are optional treatments for patients with poor or no
response to other drugs such as immunosuppressants (azathioprine, mercaptopurine, and methotrexate)
or steroids, or patients suffering from strong side effects of other IBD drugs. The US Food and Drug
Administration (FDA) has so far approved seven protein-based therapies (monoclonal antibody
therapy) for IBD treatment, namely vedolizumab, natalizumab, adalimumab, infliximab, golimumab,
certolizumab pegol [127] and ustekinumab (Table 1). Vedolizumab, the first anti-integrin approved
for use in UC, is known to be the safest biologic available with minimal side effects [128]. It binds to
α4β7 integrin (present on the surface of intestinal endothelial cells) and prevents the migration of
leukocytes into the gut. Leukocyte infiltration into the gut mucosa via interaction between integrins
on lymphocytes and their ligands on endothelial cells of intestinal lymphoid tissue (MAdCAM-1)
is another major event in the pathogenesis of IBD [129,130]. Inhibition of leukocyte migration is
possible by blocking the integrin-MAdCAM-1 interaction. Anti-adhesion agents such as natalizumab,
which blocks the α4 subunits of integrins on lymphocytes, can be an option for IBD maintenance
but is likely to be associated with increased risk for specific side effects [131]. From a comparative
meta-analysis on the efficacy of approved biologic agents, adalimumab is better than certolizumab
pegol, vedolizumab, and infliximab in both induction and maintenance of CD, while in UC, infliximab
is better than adalimumab and golimumab [132].
Cytokine-targeted therapy is another treatment option that has transformed the treatment of
IBD [124,133]. Identifying specific cytokines involved in developing particular features and phases
of IBD has enabled the design of better treatment options. Cytokines play a vital role in controlling
intestinal inflammation and the associated clinical symptoms of IBD. But some of the cytokines possess
dual functions (both pro-and anti-inflammatory), which presents difficulties in designing specific
cytokine-based therapeutic drugs. For instance, IL-6 pathway inhibition is helpful in the successful
treatment of rheumatoid arthritis, while IL-6 produced by intraepithelial lymphocytes following the
onset of inflammatory injury promotes epithelial proliferation and wound repair in murine models of
bowel injury [134]. IL-1 family cytokines such as IL-1α produced by epithelial cells are inflammatory,
while IL-1β produced by myeloid cells promotes healing and repair [135]. Thus, the development of
specific cytokine-based therapies in the future is crucial but also challenging. Even though this therapy
can control symptoms and prolong the relapse-free period for some patients, many patients fail to
respond [136]. For example, 30% of the patient shows primary non-response and 13-25% secondary
non-response with anti-TNF-α therapy [137,138].
Although the use of biologics in developed countries is common, most of these drugs are yet to
reach in developing countries. Higher manufacturing and quality control costs make biologics very
expensive, and thus affordability of such drugs by many developing countries is questionable [139].
So, introducing biologic therapies for IBD is going to impose a burden on the healthcare system
of developing countries [140]. Development of biosimilars that can substitute original biologics
with minimal treatment cost is urgent; otherwise, IBD medications may continue to remain far
from the hands of economically disadvantaged patients. Biosimilars are drugs developed with
maximum similarity to their original products of biologics in terms of purity, safety, and efficacy.
Six biosimilars including three infliximab biosimilars-Inflectra™ (infliximab-dyyb, CELLTRION, Inc.
Yeonsu-gu, Incheon, Korea), Renflexis™ (infliximab-abda, Samsung Bioepis Co., Ltd, Incheon, Korea),
and Ixifi™ (infliximab-qbtx, Pfizer Ireland Pharmaceuticals Ringaskiddy, Co. Cork, Ireland), three
adalimumab biosimilars–Amjevita™ (adalimumab-atto, Amgen Inc., Thousand Oaks, CA, USA),
Cyltezo™ (adalimumab-adbm, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA), and
Hyrimoz™ (adalimumab-adaz, Sandoz Inc., Princeton, NJ, USA) are already approved by the US FDA
for use in IBD as of 2018 [126].
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Table 1. Current drugs for inflammatory bowel diseases.
Drug Name Compound Class Trade Name(S) a
FDA
Approved
Year
Drug Class ROA Half Life a Target Mechanism of Action Major Side Effects Ref.
(I) Small Molecule Drugs
Azathioprine Imidazolyl derivative ofmercaptopurine Azasan, Imuran 1999 Immunosuppressant Oral ~2 h CD
Metabolism of azathioprine
yields 6-thioguanine
(6-TGn) nucleotide that
inhibits lymphocyte
proliferation. 6-TGN is also
thought to play role in
signalling lymphocyte
apoptosis by inhibiting
Rac1 activation in T cells.
Nausea, vomiting, leukopenia,
and increased susceptibility
to infection.
[141]
Mesalamine 5-aminosalicylic acidderivatives
Apriso, Asacol
HD, Canasa,
Delzicol, Lialda,
Pentasa, Rowasa,
SfRowasa
1997 5-Aminosalicylicacid derivative Oral
Variable;
~25 h (range:
2−296 hrs)
UC, CD
Inhibits the NF-Kβ
pathway, intestinal
epithelial cell injury
apoptosis.
Dizziness, rhinitis, sinusitis,
nasopharyngitis, back pain,
abdominal pain, skin rash,
eructation, constipation.
[142–145]
Tofacitinib Small molecule derived fromn-acylpiperidines
Xeljanz, Xeljanz
XR 2012 JAK-inhibitor Oral ~3−6 h UC
Inhibits JAK family of
proteins (JAK-1, 2, 3 &
TYK2), while in UC, it is via
inhibition of JAK-1
subsequently downregulate
IL-6 and IFN-γ.
Nasopharyngitis, headache,
skin rash, diarrhoea, herpes
zoster infection, upper
respiratory tract infection,
increased creatine phosphate.
[146]
(II) Biologics
Budesonide
Epimeric mixture of a
non-halogenated
glucocorticoid, 16 alpha,
17 alpha-(22R,S)-
propylmethylenedioxypregna-1,
4-diene-11 beta,
21-diol-3,20-dione.
Pulmicort,
Pulmicort Flehaler
2013 for UC
2001 for CD, Corticosteroids Oral
2.3 h
(children) to
3.6 h
(adults).
UC, CD
Respiratory infection, rhinitis,
nasopharyngitis, dyspepsia,
gastroenteritis, microbial
infection, otic infection,
and cough.
[142,147–149]
Infliximab Anti-TNF-α monoclonalantibody
Inflectra,
Remicade,
Renflexis
1998 Cytokines/growthfactors IV 7 to 12 days CD
Binds to TNF-α, thereby
interfering with
endogenous TNF-α activity.
Headache, abdominal pain,
nausea, anaemia, antibody
development, infection, upper
respiratory infection, sinusitis,
cough, pharyngitis.
[150–152]
Adalimumab Anti-TNF-α monoclonalantibody
Humira, Humira
Pediatric Crohn’s
Start, Humira Pen,
2002 Cytokines/growthfactors Sub-Q ~2 weeks UC, CD
Binds to TNF-α and
prevent from binding its
receptor and inhibit
subsequent inflammatory
responses.
Headache, skin rash, upper
respiratory tract infection,
sinusitis, antibody
development.
[153,154]
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Drug Name Compound Class Trade Name(S) a
FDA
Approved
Year
Drug Class ROA Half Life a Target Mechanism of Action Major Side Effects Ref.
(II) Biologics
Natalizumab
Humanized IgG4k monoclonal
antibody produced in murine
myeloma cells.
Tysabri 2004
Adhesion
molecules/
chemokines
IV 3−17 days CD
Blocks integrin (α4 subunit)
association with vascular
receptors, limiting adhesion
and transmigration of
leukocytes.
Headache, fatigue, depression,
skin rash, nausea,
gastroenteritis, abdominal
distress, urinary tract infection,
influenza, arthralgia, limb pain,
back pain, upper respiratory
tract infection, flu-like
symptoms, peripheral edema,
chest discomfort, dermatitis,
menstrual disease, diarrhoea,
tooth infection, dyspepsia,
vaginal infection, urinary tract
infection, antibody
development, muscle cramp,
cough, sinusitis, tonsillitis, and
microbial infections.
[155,156]
Certolizumab
pegol (CZP)
a recombinant humanized Fab′
fragment of a monoclonal
antibody
Cimzia, Cimzia
200mg, Cimzia
200 mg/mL,
Cimzia-200
2008
Cytokines/growth
factors/
immunosuppressant
Sub-Q 14 days CD Selectively neutralizesTNF-α.
Upper respiratory infection,
urinary tract infection,
arthralgia, rash
[142,157,158]
Golimumab
From genetically engineered
mice with human anti-TNF
antibody
Simponi, Simponi
Aria 2013
Biologic agent,
TNF blocking
agent
IV 2 weeks UC Inhibits TNF-α activity bybinding to its receptor.
Respiratory infections
(nasopharyngitis), decreased
neutrophils, and microbial
infections.
[142,159–161]
Vedolizumab Monoclonal antibody Entyvio 2014 Biologic agent IV 25 days UC, CD
Integrin antagonist; and
inhibits gut specific α4β7
integrin LPAM 1.
Upper respiratory tract
infection, nasopharyngitis,
headache, nausea, fatigue,
cough, fever, and antibody
development.
[142,162]
Ustekinumab
Human immunoglobulin (Ig)
G1 kappa monoclonal
antibody.
Stelara 2016 for CD;2019 for UC
Cytokines/growth
factor Sub-Q ~19 days UC, CD
Binds to, and interferes
with the proinflammatory
cytokines, IL-12 and IL-23.
Ustekinumab also
interferes with the
expression of monocyte
chemotactic protein-1
(MCP-1), TNF-α,
interferon-inducible
protein-10, and IL-8.
Antibody development,
nasopharyngitis, headache,
vaginal mycosis, vulvovaginal
candidiasis, erythema at
injection site, and bronchitis.
[163,164]
a All information on trade name, drug class and half-life are referred from http://www.drugs.com, and http://www.drugbank.ca. FDA, Food and Drug Administration; ROA, Route
of Administration; CD, Crohn’s disease; UC, ulcerative colitis; NF-Kβ, nuclear factor kappa β; JAK, Janus kinase; TYK2, Tyrosine kinase-2; IL, Interleukin; IFN-γ, Interferon gamma;
IV, Intravenous; TNF-α, Tumour Necrosis Factor alpha; LPAM, lymphocyte Peyer’s patch adhesion molecule.
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Several new therapeutic strategies that are currently in clinical trials include recombinant
anti-inflammatory cytokines (IFN-γ, IL-10, IL-11) and inhibitors of cell adhesion molecules (natalizumab
and etrolizumab), anti-interleukin-12/23 (ustekinumab), pro-inflammatory cytokine (IL-12), and their
receptor (IL-6R) [165–168]. Besides recombinant anti-inflammatory cytokines and inhibitors, there are
few existing drugs repurposed for treating IBD. For instance, an anti-mycobacterium drug RHB-104
(product of RedHill Biopharma Ltd based in Tel-Aviv, Israel) was repurposed for CD, and it is in
phase III trial [169]. Adacolumn is another example of an emerging treatment for IBD, which is a safe,
non-drug intervention. Adacolumn absorbs excess neutrophils and CD14+ CD16+ monocytes (which
produces TNF), and these absorbed granulocytes/monocytes, in turn, releases interleukin receptors
such as IL-1 receptor antagonist, hepatocyte growth factor and soluble TNF receptors possessing
anti-inflammatory properties [170]. This treatment showed highly positive results against UC in a few
countries, including Japan and the United Kingdom [171–173].
4.1.3. Surgical Treatment
Surgery would cause extensive loss of small bowel and disability, including permanent
ostomies [174], and it is usually performed as a last choice of treatment options, especially in a
complicated situation when prolonged medication would cause more significant disability than
surgical alternatives. Surgery in UC, unlike CD, is a curative therapy since the disease is limited to
colon and rectum, while in CD, it can only control the complication of the disease process [175]. Despite
the introduction of anti-TNF drugs, about 10–30% of UC patients ultimately require a colectomy for
the management of dysplasia or cancer [176]. While there are reports on the decreased rate of early
surgery in CD patients after treatment with anti-TNF drugs [177], as only one-third of CD patients
require surgical therapy within the first five years of their diagnosis [178].
The choice of surgery depends upon advantages as well as disadvantages associated with each
surgical option. For instance, for UC patients, restorative proctocolectomy with ileal pouch-anal
anastomosis (IPAA) is considered as standard surgical treatment, as it can maintain a usual route of
defecation by linking ileal pouch to the anal canal, and avoids ostomy permanently [179]. But chronic
pouchitis is still the main factor that limits the success of the surgical cure of UC [180]. In CD, since
the almost entire colon is involved in the inflammation, surgical decision-making is more challenging
compared to UC. It depends upon the extent and location of the inflammation in the entire colon.
If the right side of the colon is affected, right colectomy or extended right colectomy with ileocolic
anastomosis is an option. When the left colon or entire colon is affected, particularly in Crohn colitis,
total abdominal colectomy with ileorectal anastomosis is performed [181]. Surgery is not a cure for
CD since almost 28% of patients experience small bowel clinical recurrence after total colectomy
with permanent ileostomy [182]. Besides clinical recurrence, post-operative complications is another
challenge in the surgical treatment of IBD. However, due to the current laparoscopy-assisted surgery
approach, IBD patients experience improved cosmesis, reduced intraoperative blood loss, and early
recovery [183], which is lacking in open surgery. Ahmed et al. [184] and Beyer-Berjot et al. [185] also
reported that laparoscopic IPAA does not affect fecundity in females. Surgical treatment procedures
and options for both CD and UC are covered elaboratively in the guidelines developed by the European
Crohn’s and Colitis Organisation and European Society of Colo-Proctology [183,186].
While the attitude of many IBD patients on surgery as the last option remains unchanged, few
chronic patients believe that it is better to get it done ‘once and for all’ through surgical procedures
because of immense and ineffective drug therapies. It is, therefore, treated as an ‘alternative treatment
strategy’ instead and ‘last choice of treatment options.’ IBD is elusive, and it is often confused for
irritable bowel syndrome (IBS), which can complicate surgical treatments if based on the wrong
diagnosis. It is challenging to low-resource developing countries where there is a lack of expertise and
surgical technologies. This factor often influences the decision of health workers and IBD patients.
There is a need to provide training for health workers in developing countries and step-up the testing
to obtain accurate clinical numbers. The top-down approach, where government taking initiatives and
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providing advocacy to educate the public would be an excellent strategy to capture the actual IBD
incidence worldwide, especially in developing countries.
4.2. Alternative Treatment Options for IBD
It is reported that about 21–60% of IBD patients have used complementary and alternative medicine,
which includes herbal therapy, mind-body intervention, and acupuncture treatment [187–189]. Herbal
therapy and acupuncture are the two most popular treatments used by both UC and CD patients [189].
A lack of well-designed studies and randomized, double-blind clinical trials have resulted in the safety
and efficacy of complementary and alternative medicine continues to be questioned [189].
4.2.1. Botanicals Used for Treating IBD
Botanicals are popular among IBD patients owing to their perceived safety (i.e., lack of side
effects) and efficacy [190]. Amongst the herbal drugs or botanicals, Plantago ovata, Curcuma longa,
Andrographis paniculata, Aloe vera, Artemisia absinthium, Boswellia serrata, Cannabis sativa, and
Tripterygium wilfordii are the most popular herbal remedies used by IBD patients. A recent review by
Triantafyllidi and colleagues (2015) on herbal therapies for the treatment of human IBD came across
27 clinical studies on 11 herbal therapies involving 1874 IBD patients. Of the 11 herbal therapies, seven
of them had beneficial effects in UC, while four resulted in clinical remission in CD [190]. Nine out of
30 active UC patients showed clinical remission at 4 weeks after taking A. vera gel orally compared to
one out of 14 patients in the placebo group [191]. P. ovata seeds, when compared with mesalamine,
showed an equivalent effect on maintaining remission in UC after 12 months [192]. Curcumin isolated
from C. longa is another botanical, which is used for UC. Both crude extract and a pure compound
(andrographolide) isolated from A. paniculata showed efficacy against mild to moderate UC [193,194].
Similarly, A. absinthium and T. wilfordii seem to provide remission in CD [195]. In the USA, 22 states
have legalized C. sativus for medicinal use, and approximately 15–20% of American IBD patients rely
on cannabis extracts [196].
4.2.2. Helminth Therapies
Helminths, most commonly referred to as parasitic worms, have successfully co-evolved with their
human hosts through adopting a parasitic lifestyle. They can survive in the niche inside the human
host by modulating the host’s regulatory immune network [197]. Helminth therapy using hookworms
and whipworms has gained international attention. IBD patients have used these parasites for many
years despite concerns around safety and regulatory issues. Preliminary studies on the beneficial effects
of helminths in IBD were described by Elliott et al. when intra-rectal administration of TNBS failed to
induce colitis in mice infected with the blood fluke Schistosoma mansoni. Oral administration of eggs
of the whipworm Trichuris muris significantly reduced TNBS-induced colitis in IL-10−/−mice [198].
In terms of human trials, Summers and colleagues administered Trichuris suis ova to 29 patients with
active CD at intervals of three weeks for 24 weeks, and 21 of the patients were in remission at week 2,
4 indicating a safe and effective alternative therapy for CD [199]. There have been more than 20 different
clinical studies conducted in IBD using different helminths (Trichuris suis ova, Necator americanus
infective third-stage larvae (L3)), and helminth-derived products (excretory/secretory proteins from
Schistosoma mansonii and Ancylostoma caninum); this literature has been reviewed elsewhere [200,201].
However, T. suis ova therapy failed to show its clinical efficacy against active CD in stage 2 clinical
trial [202].
4.3. Challenges in the Treatment Regimens and Management of IBD
Although the overall health of IBD patients and their quality of life has improved by the earlier
diagnosis and new treatment therapies, there are still many challenges remaining unsolved. One of
the main challenges within IBD treatment and management is almost all available IBD therapies
are associated with many adverse side effects (Table 1). Optimization of diagnostic strategies and
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accessibility and affordability of new and emerging IBD therapeutic drugs are two of the many
challenges discussed below.
4.3.1. Diagnosis
Early and accurate diagnosis of IBD is crucial for better treatment outcomes. However, none
of the serological and fecal diagnostic biomarkers offer a stand-alone tool for practical evaluation,
both for suspected and established IBD. New approaches to discover biomarkers through gene
expression studies including Affymetrix GeneChip technology in whole blood [203], in mucosal
biopsies [204], mRNA expression levels in peripheral blood mononuclear cell RNA [205], and circulating
miRNA [206] have shown exciting and promising results in preliminary studies. After diagnosis,
most IBD drugs used for treatment do not produce clinical remission, or they are associated with
numerous adverse effects, including diarrhea, renal impairment, and opportunistic infections including,
tuberculosis [144,207–210]. Assessing inflammation using endoscopy is expensive as well as invasive.
The initial approach of using combined information of phenotype and serology is not enough to
distinguish CD from UC [211–213], hampering the accurate prediction of clinical outcome.
Metabolomics is emerging as a tool for comprehensive analysis of metabolites in any biological
sample, and this technique could play a vital role in IBD diagnosis, drug target identification, and
customized treatments (precision medicine) [214]. For example, the T1259 serum metabolite profiles
can differentiate IBD from healthy subjects [215]. Similarly, serum and fecal metabolite analysis proved
promising in differentiating pediatric IBD from healthy subjects via the level of FC and metabolites
such as choline [216]. The fecal FC assessment is not only used in the pediatric setting; for instance,
in UC patients, FC performs better than C-reactive protein in predicting clinical activity such as
degree of inflammation and mucosal healing [51]. As stated earlier, the in-depth role of FC in IBD,
including monitoring the effectiveness of therapy, predicting disease relapse, and postoperative
recurrence, is available in the review by Mumolo et al. [51]. Metabolite profiling can also identify
distinct biomarkers that can differentiate subtypes of IBD [217]. Analyzing metabolites using different
statistical approaches can determine similarities as well as differences in metabolite profile that can
differentiate disease phenotypes. For example, biopsies from patients with active UC contain elevated
levels of glutamine and glutathione compared to control tissue or patients with inactive UC [218].
However, metabolomic techniques and spectroscopic tools are incredibly costly, and the affordability
of such advanced facilities by developing countries remains questionable.
4.3.2. Accessibility and Affordability of IBD Treatments
The availability and affordability of newly introduced drugs is another challenge in IBD
management. Antibodies to human TNF-α inhibitors (anti-TNFs; infliximab, adalimumab, and
certolizumab pegol) are costly drugs [219]. For example, 100 mg vial of infliximab would cost USD
549.70, whose initial prescription for CD patient is 5 mg/kg body weight, meaning a cost per infusion
for a 73 kg patient comes to USD 2,198.18 and per annum USD 16,485.04/patient [220]. Similarly,
for adalimumab, initial 80 mg and 40 mg after two weeks cost USD 1,405.63, and for one year, USD
12,176.45 if infused 40 mg weekly, but these costs may subject to change with currency fluctuations.
The high cost of biologics has created disparities in usage among patients. Such disparities can be
narrowed only by introducing affordable alternative therapeutics such as biosimilars, as stated in the
earlier sections. Biosimilars are reference products easy to produce, unlike original biologics obtained
from living organisms, and thus biosimilars are estimated to reduce the original spending on biologics
by 3% over the same period [221].
Studies have shown that poor mental health is associated with disease flares and a generally poorer
IBD prognosis [97,222]. But providing adequate mental healthcare access to IBD patients remains a
hurdle even in many developed countries, including Australia. In one of the most extensive surveys
focusing on mental health needs, attitudes, and access to mental health services in people living with
IBD in Australia [98], a significant gap was identified in the mental healthcare services among IBD
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patients. Only 12% of the total of 731 participants had access to psychologists. Other studies [223–225]
also reported similar findings where more than a quarter of hospitalized IBD patients are affected
by mental distress. IBD patients suffering from depression are at higher risk of worsening disease
due to non-compliance with treatment [226]. Thus, regular provision of mental health screening and
reasonable access to psychologists or mental health professionals besides treatment could be another
key strategy towards improving the quality of life of IBD patients, which can subsequently reduce the
cost burden associated with disability.
5. Anti-Inflammatory Activities of Natural Products
Natural products, including plants, animals, fungi, microorganisms, and marine organisms
produce secondary metabolites with rich structural diversity, which synthetic and combinatorial
chemistry approaches are lacking, and for this reason alone, natural products are viable sources of
drugs [227–229]. Four main bio-rational search strategies guide the identification of novel drug lead
compounds from natural sources. They are: (i) ethnobotanically directed approach, (ii) ecologically
directed approach, (iii) chemically directed approach, and (iv) random selection and screening
(Figure 8) [230]. Very often, approaches (i), (ii) and (iv) are combined by researchers for efficiently
discovering novel drug lead compounds.
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Therapeutic agents derived from natural sources may be small molecules or biologics [231].
Small molecule natural products with anti-inflammatory properties hold great potential for clinical
translation (Table 2). The Anti-inflammatory Compounds Database (freely accessible at http://956023.
ichengyun.net/AICD/index.php.) has recorded over 79,781 small molecules of the therapeutic potential
and a total of 232 inflammation-related targets [232]. Ten out of 2,892 natural products showed
potent efficacy as anti-inflammatory drug lead candidates when assessed for their anti-inflammatory
activity in the prediction model constructed using iterative stochastic elimination algorithm. However,
of these 10 natural products, only three (moupinamide, hypaphorine, and capsaicin) have thus far
been experimentally reported as an anti-inflammatory and require further study on the remaining
seven [233].
5.1. Techniques and Biological Assays Used in the Discovery of Anti-Inflammatory Extracts and Drug Leads
‘Omics’ science such as genomics, proteomics, lipidomics, and metabolomics has enabled the
comprehensive characterization of biomolecules of diverse fauna and flora, facilitating a better
understanding of disease mechanisms. Of these ’omics’ approaches, metabolomics remains the
least applied and under-utilized. A combined approach using metabolomic profiling and in vivo
anti-inflammatory activity studies of identified metabolites in various animal models such as colitis
models has given insights into disease mechanism and identifying potential therapeutic targets.
For example, Gas Chromatography-Mass Spectrometry (GCMS)-based metabolomic profiling of
dextran sulfate sodium (DSS)-induced colitis in mice had proven useful for monitoring disease
progression and differentiating active from inactive colitis [234]. Furthermore, multivariate indexes
developed based on Fischer linear classifiers from plasma amino acid profiles (aminogram) could
be used as a discriminator between CD and UC patients as well as in monitoring disease activity
during the progression of IBD [235]. Metabolomics techniques use Nuclear Magnetic Resonance
(NMR), GCMS, Liquid Chromatography-Mass Spectrometry (LCMS), and hyphenated spectroscopies
for bulk identification of compounds present in the crude and complex mixtures of natural products.
These same spectroscopies, in combination with High-Performance Liquid Chromatography (HPLC),
Infrared Red (IR), and X-Ray Crystallography, are used for compound purification and structure
elucidation [230]. Pure compounds, once isolated, must be screened for their anti-inflammatory
activities using different in vitro assays and in vivo disease models.
A comprehensive understanding of the complex disease mechanisms that underpin IBD is crucial
for identifying targets for treatment, and subsequently to design novel drugs that hit these targets.
The application of different murine models of IBD has profoundly improved the understanding
of IBD pathogenesis and assisted in the development of novel therapeutic strategies. As of now,
researchers use at least 66 different kinds of animal models to study IBD [236,237]. These disease models
are chemically-induced, cell-transfer, congenic mutant, and genetically modified models. The use
of genetically engineered mouse models that spontaneously develop colitis has enabled a deeper
understanding of the complex immunopathogenesis mechanisms of IBD. The DSS–induced colitis
model is one of the most widely used models since it is easy to implement within a short timeframe
with minimal cost [237]. Other popular models include TNBS–induced colitis, oxazolone-induced
colitis, cell transfer models (e.g., adoptive T-cell transfer), and IL-10 knockout [238]. There are many
in vitro screening assays to assess the anti-inflammatory effects of various natural products, including
cyclooxygenase-2 (COX-2) inhibitory effect assay, bacteria-derived lipopolysaccharide [239]-induced
inflammation [239] in human cells (macrophages, and peripheral blood mononuclear cells-PBMCs),
myeloperoxidase (MPO) activity assay and inducible nitric oxide synthase (iNOS) inhibitory activity.
5.2. Anti-Inflammatory Activities of Plant Extracts and Compounds
Plants produce secondary metabolites, including alkaloids, flavonoids, and phenolics
phytochemicals, which can possess anti-inflammatory properties. According to reviews by
Ahmad et al. [240], Azab et al. [241], Peng et al. [242], and Salaritabar et al. [243], there is a need for
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more studies to analyze the efficacy of plant-derived materials/compounds using chronic IBD models
and clinical trials. Some natural compounds that have demonstrated anti-inflammatory activities are
catechins from Camellia sinensis [244], berberine [245] and berberrubine from Berberis vulgaris [246],
resveratrol from Polygonum cuspidatum [247], 14-O-acetylneoline from Aconitum laciniatum [248],
Bromelain from Ananas comosus [249], capnoidine from Corydalis dubia [250], zedoarondiol from
Curcuma heyneana [251], and other pigmented vegetables and fruits. Although numerous pure natural
compounds show a range of biological activities, including anti-inflammatory activity, and some are
toxic to human cells. While curcumin from C. longa is safe after six human trials using concentrations
as high as 8000 mg/day for 3 months [252], nevertheless, converting new drug leads from natural
sources into effective and safe therapeutic drugs for human consumption may be still a complicated
and challenging task. Some promising plant-derived compounds that demonstrate anti-inflammatory
activity in various colitis animal models are presented in Tables 2 and 3.
Table 2. Plant-derived compounds in various phases of clinical trials for Inflammatory Bowel Diseases a.
Name Plant Disease/Condition Target/ Objective Clinical Phase Location(s)/ Developer
Berberine Coptis chinensisFranch UC
Assess the safety of
berberine (berberine
chloride) for UC patients
in clinical remission
while receiving
maintenance therapy
with mesalamine.
Phase I
Northwestern University
Chicago, Illinois, United
States. Fourth Military
Medical University
Xi’an, Shaanxi, China.
Epigallocatechin-
3-gallate C. sinensis L.
Mild to
moderately
active UC
Determine the Safety of
an oral dose of green tea
extract (Polyphenon E®)
as a preliminary
evidence to support its
efficacy in UC.
Phase II
University of Louisville
Clinical Research Center
Louisville, Kentucky,
United States.
Triptolide
Tripterygium
wilfordii
Hook. F.
CD
Assess the effect and
safety of Tripterygium
Glycosides in the
treatment of CD for
induction remission and
compare the therapeutic
effect with patients who
received mesalamine.
Phase II
Phase III
General Surgery
Institute, Jinling
Hospital Nanjing,
Jiangsu, China.
Curcumin
(1,7-Bis(4-hydroxy-
3-methoxyphenyl)-1,
6-heptadiene-3,
5-dione)
C. longa L.
Both UC and
CD
Determine the
tolerability of curcumin
in pediatric IBD patients.
Phase I
Seattle Children’s
Hospital Seattle,
Washington,
United States.
CD
Study the effect of
curcumin combined
with thiopurines in the
prevention of
post-operative
recurrence of CD.
Phase III
University Hospital of
Clermont-Ferrand
(CHU),
Clermont-Ferrand,
France.
UC
Evaluate the efficacy of
combined therapy of
curcumin + 5ASA versus
5ASA alone on mild to
moderate UC patients.
Phase III Sheba Medical CenterRamat Gan, Israel.
a All resources were obtained from www.clinicaltrials.gov. UC, ulcerative colitis; CD, Crohn’s disease.
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Table 3. Natural products showing protective functions in various animal colitis models/cell lines.
Source Isolated Compounds Animal Models/Cell Lines The Main Effect on Inflammation Ref
A. laciniatum 14-O-acetylneoline TNBS-induced mice. Protects colonic inflammation and reduces colonic IFN-γmRNA levels. [248]
Andrographis paniculata Ethanolic extract Pelvic inflammatory disease inducedSprague Dawley rats. Inhibits NF-kB signal pathway. [253]
Ananas comosus Bromelain
LPS-induced human intestinal
adenocarcinoma cell line (HT29 cells);
DSS-induced colitis mice.
Reduces mRNA expression of proinflammatory cytokines
IL-8 and TNF-α in LPS challenged HT29 cells; reduces
inflammation in DSS-induced colitis mice.
[249]
Amphipterygium adstringens Alcoholic extract DSS-induced mice BALB/c mice. Significant reduction in levels of inflammatory cytokinesTNF-α, IFN-γ, and IL-1β. [254]
Aralia continentalis Kaurenoic acid(ent-kaur-16-en-19-oic acid) LPS-induced RAW264.7 macrophages.
Significant reduction of the diameter in
carrageenan-induced paw edema mice model; Suppression
of the COX-2 activity.
[255]
Basella rubra Methanolic extract Oxazolone-induced rats. Enhances recovery from colon inflammation. [256]
Cinnamomum verum Trans-cinnamaldehyde and p-cymene THP1 monocyte-macrophage cell lineTIB-202 (ATCC).
Significant reduction of the LPS-dependent IL-8 secretion in
THP1 monocytes. [257]
C. dubia Capnoidine TNBS-induced colitis mice. Reduces colon pathology and inflammation; reducesp-IκB-α (Ser32) and p-NF-κB p65 (Ser536) levels. [250]
C. heyneana Zedoarondiol LPS-induced macrophage cell.
Dose dependent inhibition of LPS-stimulated NO,
prostaglandin E2, IL-1β, IL-6, and TNF-α in RAW 264.7
macrophage and mouse peritoneal macrophage cells.
[251]
Cryptostegia grandiflora Leaf ethanol extract 12-O -tetradecanoyl-phorbol-13-acetate(TPA) treated mice.
Reduces inflammation and MPO in ear tissue; reduces
edema and leukocyte infiltration. [258]
Euphorbia tirucalli Euphol DSS- and TNBS-induced mice.
Inhibits the levels and expression of IL-1β, CXCL1/KC,
MCP-1, MIP-2, TNF-α and IL-6 in colonic tissue; reduces the
expression of NOS2, VEGF, and Ki67 in colonic tissue.
[259]
Evodia rutaecarpa Evodiamine, Rutaecarpine LPS induced-RAW 267.7 cell. Inhibits PGE2 production. [260]
Evodia fructus Dehydroevodiamine LPS-induced RAW 264.7macrophages cells.
Produces mark PGE2 and COX-2 inhibition via inhibiting
the NF-κB activity. [260]
Fissistigma oldhamii
7′-(3′,4′-dihydroxyphenyl)-n-
[(4-methoxyphenyl) ethyl]
propenamide (Z23)
LPS-induced RAW 264.7 macrophages. Exhibits mark PGE2 inhibition via suppressing theCOX-2 expression. [261]
Ganoderma lucidum DMSO extract LPS stimulation on cancer cells. Reduces the levels of IL-6, IL-8, MMP-2, MMP-9 in breastcancer cells. [262]
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Source Isolated Compounds Animal Models/Cell Lines The Main Effect on Inflammation Ref
Ipomoea asarifolia Aqueous extract Dinitrobenzene sulfonic acid(DNBS)-induced colitis in mice.
Reduces MPO activity; down-regulates the gene expression
of JNK1, NF-kβ-p65, and STAT3; decreases the level of
TNF-α, and IL-1β, and increases IL-10.
[263]
Millettia pulchra Ethanol extract and isolated compoundlanceolatin B Xylene-induced ear edema mice. Reduces pain; inhibits NO synthesis. [264]
Panax quinquefolius Ginsenosides azoxymethane [265]/ DSS mouse model. Inhibits inflammatory cytokines and restores microbiomeinhibited by AOM/DSS. [266]
P. quinquefolius Aqueous extract Acetic acid-induced UC rats. Heals colon tissues. [267]
Gallic acid TNBS-induced UC in rats. Reduces MPO activity. [268]
Penicillium paxillin Pyrenocine A LPS-induced RAW 264.7 cell line. Inhibits nitrite production and the synthesis ofproinflammatory cytokines and PGE2. [269]
Pistacia atlantica Methanolic leaf extract Carrageenan-induced mice. Reduces hind paw edema. [270]
Serpylli herba Aqueous extract TNBS-induced rat colitis.
Reduces the expression of proinflammatory cytokines
(TNF-α, IL-1β, IFN-γ, IL-6, and IL-17), the chemokine
(MCP-1), and the adhesion molecule (ICAM-1).
[271]
Stephania tetrandra Methanolic extract of roots Silica stimulated human monocytes. Reduces the level of IL-6. [272]
Sida cordifolia
5′-Hydroxymethyl-1′-
(1,2,3,9-tetrahydro-pyrrolo [2,1-b]
quinazolin-1-yl)-heptan-1-one)
Carrageenan-induced rat paw
edema model. Inhibits rat paw edema. [273]
Styrax japonica Styraxosides A RAW 264.7 Cells.
Inhibits protein the expression levels of nitric oxide
synthase (NOS) and cyclooxygenase-2 (COX-2); mRNA
expression levels of NOS and COX-2, TNF-α, IL-1β; inhibits
DNA binding activity of NF-kB pathway.
[274]
IFN-γ, interferon gamma; LPS, lipopolysaccharide; DSS, dextran sulfate sodium; BALB/c, Bagg Albino C; RAW, Ralph And William’s cell line; COX-2, cyclooxygenase-2; THP1, human
monocytic leukemia cell line; NO, nitric oxide; MPO, myeloperoxidase; PGE2, prostaglandin E2; DMSO, dimethyl sulfoxide; MMP, matrix metalloproteinase.
J. Clin. Med. 2020, 9, 1273 23 of 39
5.3. Fungal-Derived Anti-Inflammatory Drug Leads
To date, more than 133 small molecules were isolated and identified from marine-derived fungi,
of which 50 have been tested and showed various anti-inflammatory activities [275]. Small molecules
preussins derived from Aspergillus flocculosus 16D-1 (a fungus isolated from the marine sponge
Phakellia fusca) showed potent anti-inflammatory activity (IL-6 inhibitory effects in LPS-induced
human monocytic leukemia cell line, THP1) [276]. Graphostromanes F and Khusinol B isolated
from Graphostroma sp showed inhibition of LPS-induced nitric oxide (NO) production in RAW264.7
macrophages [277,278]. Another small molecule mangicol (A isolated and identified from a marine
fungal isolate Fusarium heterosporum) also showed anti-inflammatory activity in the phorbol myristate
acetate-induced mouse ear edema model [279]. Asperflavin produced by the marine-derived fungus,
Eurotium amstelodami suppresses iNOS, and pro-inflammatory cytokine production with minimal
cytotoxicity [280]. Thus, looking at the great diversity of molecules and their anti-inflammatory
activities, natural products, particularly small molecules produced by fungi and related organisms,
can offer great potential in developing novel therapeutic drugs against IBD with minimal side effects.
Secondary metabolites produced by fungi are also drug leads for many immunosuppressants used
in related inflammatory disorders such as mycophenolic acid (produced by Penicillium spp.) [281],
cyclosporin (produced by Tolipocladium inflatum) [282], and fingolimod (GilenyaTM) derived from
myriocin (produced by Isaria sinclairii) [283]. Many such molecules and metabolites derived from
various fungi and macrofungi (mushrooms) with potent anti-inflammatory properties are reviewed
elsewhere [284,285].
5.4. Helminth-Derived Anti-Inflammatories
Studying parasitic helminths and metabolites produced by them at different stages of their life
cycles could help to reveal completely novel approaches to suppressing inflammation. Indeed, there
is already a substantial body of literature that describes the immunoregulatory properties of these
parasites ranging from clinical trials with experimental human helminth infections to animal studies
with isolated or synthesized single molecules. Helminths are capable of secreting a vast array of
immunoregulatory molecules, including proteins, glycans, lipids, nucleic acids, and small molecule
metabolites. For comprehensive reviews on this topic, see [286,287]. Crude excretory/secretory
(ES) products or rude soluble extracts (which contain many distinct groups of metabolites) from
helminths protect against colitis in mice. For example, the tapeworm Hymenolepis diminuta in
dinitrobenzene sulfonic acid (DNBS)-induced colitis [288], the roundworm nematode Trichinella spiralis
in TNBS-induced colitis [289], and the platyhelminth blood fluke S. mansoni in adoptive T cell transfer
colitis [290]. Wangchuk et al. [291] showed that ES metabolites from the hookworm Ancyclostoma
caninum could suppress colitis in mouse models by inhibiting the production of inflammatory
cytokines. Additionally, Wangchuk et al. [292] identified 54 small molecules from the ES products
of the gastrointestinal nematodes Trichuris muris and Nippostrongylus brasiliensis, of which 17 small
molecules possess potent pharmacological activities in the literature. They also reported 49 metabolites
from dog tapeworm Dipylidium caninum, out of which 12 were bioactive [293]. These studies highlight
the untapped metabolomes of parasitic helminths from a therapeutics discovery angle and warrant
further attention in the future.
5.5. Anti-Inflammatory Peptides
Peptide-based therapeutics are gaining more attention in medical research since several small
peptides are proven to have efficacy in experimental colitis in mice [294–297]. However, delivery of
peptides is challenging due to their unstable nature and rapid clearance from circulation. However,
when an annexin A1-derived tripeptide MC-12 was grafted within the scaffold of the cyclic peptide
sunflower trypsin inhibitor 1 (SFTI-1, isolated from Helianthus annuus seeds), it ameliorated acute colitis
in mice and displayed enhanced stability [298]. Similarly, grafting this tripeptide into the disulfide-rich
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peptide linaclotide also improved the stability and bioactivity of the tripeptide [299]. These examples
indicate that peptides possess scope for clinical development in IBD if there are promising scaffold
peptides like SFTI-1 and linaclotide that can encapsulate and stabilize the bioactive sequence within
the peptides of interest.
6. Conclusions
IBD continues to cause substantial morbidity and massive productivity loss globally. A single
mechanism responsible for IBD is difficult to determine due to the complex interplay of multiple
factors, including the host’s genetic predisposition and environmental factors. The relapsing nature of
IBD demands repeated treatment, implicating a substantial financial burden to individual patients
and the healthcare system, especially in developing nations. The development of SMDs (such as
tofacitinib and 5-ASA derivatives mesalamine) and new biologics (integrin antagonist, Entyvio) has
revolutionized the treatment of IBD. With the introduction of biologics such as anti-TNF drugs, there
is a decreased rate of early surgery in IBD patients. However, there are still challenges with the
existing IBD treatment regimens, and new therapeutic modalities are urgently needed. Many small
molecules or compounds derived from natural products based on traditional use knowledge have
shown promising anti-inflammatory activities in various experimental murine colitis models with
few side effects and have the potential to be next-generation drugs. Some small molecules derived
from plants such as berberine, curcumin, epigallocatechin-3-gallate, and triptolide are already in
clinical trials. An anti-mycobacterium drug (Oral capsule RHB-104), which is repurposed for treating
IBD and currently in phase III trial, is another good example of potential IBD drug in the pipeline.
Designing a new and non-invasive IBD drug delivery system targeting specific receptors in the colon
could primarily help to mitigate the current treatment challenges associated with many side effects.
Ethnopharmacology knowledge-guided drug discovery, mainly focusing on small molecules and
peptides of medicinal plants, holds promise for the development of safe and novel therapeutics for IBD.
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